First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Stuart L. Goldberg, Jorge E. Cortes, Carlo Gambacorti-Passerini, Rüdiger Hehlmann, H. Jean Khoury, Mauricette Michallet, Ron L. Paquette, Bengt Simonsson, Teresa Zyczynski, Aimee Foreman, Elisabetta Abruzzese, David Andorsky, Aart Beeker, Pascale Cony-Makhoul, Richard Hansen, Elza Lomaia, Eduardo Olavarria, Michael J. Mauro

Research output: Contribution to journalArticle

Abstract

Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n = 416), dasatinib (n = 418) or nilotinib (n = 408) in the US and 6 European countries in routine clinical practice. Twelve-month follow-up data of 1242 prospective patients (enrolled October 01 2010-September 02 2015) are reported. 81% of patients had baseline comorbidities. Treatment selection was based on perceived efficacy over patient comorbidity profile. There was a predominance of imatinib-treated patients enrolled earlier in the study, with subsequent shift toward dasatinib- and nilotinib-treated patients by 2013/2014. Monitoring for either CyR/MR improved over time and was documented for 36%, 82%, and 95% of patients by 3, 6, and 12 months, respectively; 5% had no documentation of CyR/MR monitoring during the first year of therapy. Documentation of MR/CyR testing was higher in Europe than the US (P <.001) and at academic versus community practices (P =.001). Age <65 years, patients being followed at sites within Europe, those followed at academic centers and patients no longer on first-line therapy were more likely to be monitored by 12 months. SIMPLICITY demonstrates that the NCCN and ELN recommendations on response monitoring have not been consistently translated into routine clinical practice. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted.

Original languageEnglish (US)
Pages (from-to)1214-1223
Number of pages10
JournalAmerican Journal of Hematology
Volume92
Issue number11
DOIs
StatePublished - Nov 2017
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Therapeutics
Documentation
Comorbidity
Cytogenetics
Protein-Tyrosine Kinases
Observational Studies

ASJC Scopus subject areas

  • Hematology

Cite this

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice : SIMPLICITY. / Goldberg, Stuart L.; Cortes, Jorge E.; Gambacorti-Passerini, Carlo; Hehlmann, Rüdiger; Khoury, H. Jean; Michallet, Mauricette; Paquette, Ron L.; Simonsson, Bengt; Zyczynski, Teresa; Foreman, Aimee; Abruzzese, Elisabetta; Andorsky, David; Beeker, Aart; Cony-Makhoul, Pascale; Hansen, Richard; Lomaia, Elza; Olavarria, Eduardo; Mauro, Michael J.

In: American Journal of Hematology, Vol. 92, No. 11, 11.2017, p. 1214-1223.

Research output: Contribution to journalArticle

Goldberg, SL, Cortes, JE, Gambacorti-Passerini, C, Hehlmann, R, Khoury, HJ, Michallet, M, Paquette, RL, Simonsson, B, Zyczynski, T, Foreman, A, Abruzzese, E, Andorsky, D, Beeker, A, Cony-Makhoul, P, Hansen, R, Lomaia, E, Olavarria, E & Mauro, MJ 2017, 'First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY', American Journal of Hematology, vol. 92, no. 11, pp. 1214-1223. https://doi.org/10.1002/ajh.24887
Goldberg, Stuart L. ; Cortes, Jorge E. ; Gambacorti-Passerini, Carlo ; Hehlmann, Rüdiger ; Khoury, H. Jean ; Michallet, Mauricette ; Paquette, Ron L. ; Simonsson, Bengt ; Zyczynski, Teresa ; Foreman, Aimee ; Abruzzese, Elisabetta ; Andorsky, David ; Beeker, Aart ; Cony-Makhoul, Pascale ; Hansen, Richard ; Lomaia, Elza ; Olavarria, Eduardo ; Mauro, Michael J. / First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice : SIMPLICITY. In: American Journal of Hematology. 2017 ; Vol. 92, No. 11. pp. 1214-1223.
@article{dbde1dea28d8423bae659766956b5b2e,
title = "First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY",
abstract = "Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n = 416), dasatinib (n = 418) or nilotinib (n = 408) in the US and 6 European countries in routine clinical practice. Twelve-month follow-up data of 1242 prospective patients (enrolled October 01 2010-September 02 2015) are reported. 81{\%} of patients had baseline comorbidities. Treatment selection was based on perceived efficacy over patient comorbidity profile. There was a predominance of imatinib-treated patients enrolled earlier in the study, with subsequent shift toward dasatinib- and nilotinib-treated patients by 2013/2014. Monitoring for either CyR/MR improved over time and was documented for 36{\%}, 82{\%}, and 95{\%} of patients by 3, 6, and 12 months, respectively; 5{\%} had no documentation of CyR/MR monitoring during the first year of therapy. Documentation of MR/CyR testing was higher in Europe than the US (P <.001) and at academic versus community practices (P =.001). Age <65 years, patients being followed at sites within Europe, those followed at academic centers and patients no longer on first-line therapy were more likely to be monitored by 12 months. SIMPLICITY demonstrates that the NCCN and ELN recommendations on response monitoring have not been consistently translated into routine clinical practice. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted.",
author = "Goldberg, {Stuart L.} and Cortes, {Jorge E.} and Carlo Gambacorti-Passerini and R{\"u}diger Hehlmann and Khoury, {H. Jean} and Mauricette Michallet and Paquette, {Ron L.} and Bengt Simonsson and Teresa Zyczynski and Aimee Foreman and Elisabetta Abruzzese and David Andorsky and Aart Beeker and Pascale Cony-Makhoul and Richard Hansen and Elza Lomaia and Eduardo Olavarria and Mauro, {Michael J.}",
year = "2017",
month = "11",
doi = "10.1002/ajh.24887",
language = "English (US)",
volume = "92",
pages = "1214--1223",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice

T2 - SIMPLICITY

AU - Goldberg, Stuart L.

AU - Cortes, Jorge E.

AU - Gambacorti-Passerini, Carlo

AU - Hehlmann, Rüdiger

AU - Khoury, H. Jean

AU - Michallet, Mauricette

AU - Paquette, Ron L.

AU - Simonsson, Bengt

AU - Zyczynski, Teresa

AU - Foreman, Aimee

AU - Abruzzese, Elisabetta

AU - Andorsky, David

AU - Beeker, Aart

AU - Cony-Makhoul, Pascale

AU - Hansen, Richard

AU - Lomaia, Elza

AU - Olavarria, Eduardo

AU - Mauro, Michael J.

PY - 2017/11

Y1 - 2017/11

N2 - Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n = 416), dasatinib (n = 418) or nilotinib (n = 408) in the US and 6 European countries in routine clinical practice. Twelve-month follow-up data of 1242 prospective patients (enrolled October 01 2010-September 02 2015) are reported. 81% of patients had baseline comorbidities. Treatment selection was based on perceived efficacy over patient comorbidity profile. There was a predominance of imatinib-treated patients enrolled earlier in the study, with subsequent shift toward dasatinib- and nilotinib-treated patients by 2013/2014. Monitoring for either CyR/MR improved over time and was documented for 36%, 82%, and 95% of patients by 3, 6, and 12 months, respectively; 5% had no documentation of CyR/MR monitoring during the first year of therapy. Documentation of MR/CyR testing was higher in Europe than the US (P <.001) and at academic versus community practices (P =.001). Age <65 years, patients being followed at sites within Europe, those followed at academic centers and patients no longer on first-line therapy were more likely to be monitored by 12 months. SIMPLICITY demonstrates that the NCCN and ELN recommendations on response monitoring have not been consistently translated into routine clinical practice. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted.

AB - Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n = 416), dasatinib (n = 418) or nilotinib (n = 408) in the US and 6 European countries in routine clinical practice. Twelve-month follow-up data of 1242 prospective patients (enrolled October 01 2010-September 02 2015) are reported. 81% of patients had baseline comorbidities. Treatment selection was based on perceived efficacy over patient comorbidity profile. There was a predominance of imatinib-treated patients enrolled earlier in the study, with subsequent shift toward dasatinib- and nilotinib-treated patients by 2013/2014. Monitoring for either CyR/MR improved over time and was documented for 36%, 82%, and 95% of patients by 3, 6, and 12 months, respectively; 5% had no documentation of CyR/MR monitoring during the first year of therapy. Documentation of MR/CyR testing was higher in Europe than the US (P <.001) and at academic versus community practices (P =.001). Age <65 years, patients being followed at sites within Europe, those followed at academic centers and patients no longer on first-line therapy were more likely to be monitored by 12 months. SIMPLICITY demonstrates that the NCCN and ELN recommendations on response monitoring have not been consistently translated into routine clinical practice. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted.

UR - http://www.scopus.com/inward/record.url?scp=85030213233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030213233&partnerID=8YFLogxK

U2 - 10.1002/ajh.24887

DO - 10.1002/ajh.24887

M3 - Article

C2 - 28815757

AN - SCOPUS:85030213233

VL - 92

SP - 1214

EP - 1223

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -